This may explain why, in our series, the frequency of HER2 low tumors is slightly lower than in some other recent series [17]: Indeed eBC eligible for neoadjuvant strategy may have different characteristics from those of all breast tumors, including small and indolent tumors (HR expression, proliferative features...). This evidence concerns the gene ERBB2 and breast neoplasm.